Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Subscribe To Our Newsletter & Stay Updated
